沙库巴曲缬沙坦钠联合呋塞米治疗慢性心力衰竭的效果及对肝肾功能的影响

Effect of sacubitril valsartan sodium combined with furosemide in the treatment of chronic heart failure and its influence on liver and kidney function

目的探讨沙库巴曲缬沙坦钠联合呋塞米治疗慢性心力衰竭的效果及对肝肾功能的影响。方法择取2021年10月至2022年12月收治的80例慢性心力衰竭患者为研究对象,以随机数字表法将其分为对照组与观察组,各40例。对照组给予呋塞米治疗,观察组在对照组基础上联合沙库巴曲缬沙坦钠治疗。比较两组的治疗效果。结果观察组的治疗总有效率为92.50%,显著高于对照组的75.00%,差异具有统计学意义(P<0.05)。治疗后,观察组的左心室射血分数(LVEF)、心排血量(CO)大于对照组,左心室舒张末期内径(LVEDD)、室间隔厚度(IVST)小于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的脑钠肽(BNP)、门冬氨酸氨基转移酶(AST)、胱抑素C(CysC)、血肌酐(Scr)水平低于对照组,差异具有统计学意义(P<0.05)。结论沙库巴曲缬沙坦钠联合呋塞米治疗慢性心力衰竭患者的效果显著,不仅能够调节BNP水平,改善心功能,而且不会对肝肾功能造成不良影响,具有较高的安全性,值得推广。

Objective To investigate the effect of sacubitril valsartan sodium combined with furosemide in the treatment of chronic heart failure and its influence on liver and kidney function.Methods A total of 80 patients with chronic heart failure admitted from October 2021 to December 2022 were selected as the research objects and divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with furosemide,and the observation group was treated with sacubitril valsartan sodium on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was 92.50%,which was significantly higher than 75.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)and cardiac output(CO)in the observation group were larger than those in the control group,the left ventricular end-diastolic dimension(LVEDD)and interventricular septum thickness(IVST)were smaller than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of brain natriuretic peptide(BNP),aspartate transaminase(AST),cystatin C(CysC)and serum creatinine(Scr)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Sacubitril valsartan sodium combined with furosemide in the treatment of patients with chronic heart failure has a significant effect.It can not only regulate the level of BNP,improve cardiac function,but also does not have adverse effects on liver and kidney function,which has high safety and is worthy of promotion.